“compound 18” is an oral inducer of fetal hemoglobin (HbF) intended to treat anemias such as sickle cell disease and beta-thalassemia. The authors identified a weak hit (>10 uM) from a high-throughput phenotypic screen using human umbilical cord blood-derived erythroid progenitor cells. Optimization led to the azaspiro[3.3]heptane-containing [...]
< 1 minute read
Sep. 18, 2021
Compound 18: An Orally Available Fetal Hemoglobin Inducer
"compound 18"
orally available fetal hemoglobin inducer oral induction of fetal hemoglobal in cyno from phenotypic screen and ADME opt. Bioorg. Med. Chem. Lett., Jul. 24, 2020 Daiichi-Sankyo, Tokyo, JP / Asubio